US-based Open Book Extracts is in the process of achieving compliance with novel food regulations as it prepares to make its move on the European market.
The major cannabinoid manufacturer has announced it has joined the European Industrial Hemp Association’s (EIHA) Novel Food Consortium in order to gain novel food approval regarding the distribution of CBD ingredients.
The EIHA Novel Food Consortium, officially launched in June 2020, is the Association’s project aimed at clearing the way for hemp foods and extracts – including CBD – in the UK and European Union member states.
By joining the Consortium established by the EIHA, Open Book Extracts is joining forces with other companies to pursue the safety studies to provide safe and ready access to cannabinoid-based products throughout the UK and EU.
CEO Dave Neundorfer said: “We are witnessing a pivotal moment in history when the global appetite for access to cannabinoids is very high.
“We see this in the US with many recent positive discussions among US congressional officials to pass legislation for federal legalisation of cannabis but also new bills for CBD to be regulated as a dietary supplement.
“We appreciate the EIHA and its members working together to respond to a common challenge by investing in unprecedented studies, and look forward to the EU quickly solidifying their plans to implement a parallel framework where these same studies can be applied.
“We are also pleased to offer our clients the ability to sublicense our membership in the Novel Foods Consortium to bring their premium CBD products to market in the UK and eventually the EU.”
Powered by their cGMP operations in North Carolina and a team of world-class scientists, Open Book Extracts offers one of the largest portfolios of cannabinoid isolates at purity, including CBD, CBG, CBN, CBC, and THCV, all at greater than 99 percent purity.
It also produces formulation services and turnkey finished good manufacturing including edibles, softgels, tablets, tinctures, and a full range of topical products.
Neundorfer said: “As Open Book Extracts proceeds down the path to achieve compliance with world-wide regulations, we are positioned to become the leading global supplier of cannabinoids while continuing to maintain 100 percent dedication to premium quality, science-driven consistency, sustainability, transparency, and positive, trustworthy relationships with our clients and community.”
This article originally appeared on www.cannabishealthnews.co.uk